248 related articles for article (PubMed ID: 33131698)
1. Fingolimod (FTY720) prevents chronic rejection of rodent cardiac allografts through inhibition of the RhoA pathway.
Chen W; Chen W; Chen S; Uosef A; Ghobrial RM; Kloc M
Transpl Immunol; 2021 Apr; 65():101347. PubMed ID: 33131698
[TBL] [Abstract][Full Text] [Related]
2. Siponimod (Mayzent) Downregulates RhoA and Cell Surface Expression of the S1P1 and CX3CR1 Receptors in Mouse RAW 264.7 Macrophages.
Uosef A; Vaughn N; Chu X; Elshawwaf M; Abdelshafy AAA; Elsaid KMK; Ghobrial RM; Kloc M
Arch Immunol Ther Exp (Warsz); 2020 Jun; 68(3):19. PubMed ID: 32488676
[TBL] [Abstract][Full Text] [Related]
3. FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin.
Huu DL; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Fujimoto M
Arthritis Rheum; 2013 Jun; 65(6):1624-35. PubMed ID: 23508350
[TBL] [Abstract][Full Text] [Related]
4. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
Hiestand PC; Rausch M; Meier DP; Foster CA
Prog Drug Res; 2008; 66():361, 363-81. PubMed ID: 18416311
[TBL] [Abstract][Full Text] [Related]
5. [New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
Chiba K
Yakugaku Zasshi; 2009 Jun; 129(6):655-65. PubMed ID: 19483408
[TBL] [Abstract][Full Text] [Related]
6. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Brinkmann V
Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
[TBL] [Abstract][Full Text] [Related]
7. [A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
Chiba K
Nihon Rinsho Meneki Gakkai Kaishi; 2009 Apr; 32(2):92-101. PubMed ID: 19404007
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of RhoA and mTORC2/Rictor by Fingolimod (FTY720) induces p21-activated kinase 1, PAK-1 and amplifies podosomes in mouse peritoneal macrophages.
Chen W; Ghobrial RM; Li XC; Kloc M
Immunobiology; 2018 Nov; 223(11):634-647. PubMed ID: 30005970
[TBL] [Abstract][Full Text] [Related]
9. FTY720 prevents chronic rejection of rat heterotopic cardiac allografts.
Chueh SC; Chen JR; Chen J; Lai MK
Transplant Proc; 2001; 33(1-2):542-3. PubMed ID: 11266948
[No Abstract] [Full Text] [Related]
10. Protection of mouse small bowel allografts by FTY720 and costimulation blockade.
Yan S; Rodriguez-Barbosa JI; Pabst O; Beckmann JH; Brinkmann V; Förster R; Hoffmann MW
Transplantation; 2005 Jun; 79(12):1703-10. PubMed ID: 15973172
[TBL] [Abstract][Full Text] [Related]
11. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
[TBL] [Abstract][Full Text] [Related]
12. ACS chemical neuroscience molecule spotlight on gilenya (fingolimod; FTY720).
Hopkins CR
ACS Chem Neurosci; 2011 Mar; 2(3):116-7. PubMed ID: 22778861
[No Abstract] [Full Text] [Related]
13. Effect of FTY720 and ex vivo graft irradiation in rat small bowel transplantation: expression of mucosal addressin cell adhesion molecule-1.
Sugito K; Inoue M; Ikeda T; Hagiwara N; Koshinaga T; Kusafuka T
Surg Today; 2008; 38(1):38-41. PubMed ID: 18085360
[TBL] [Abstract][Full Text] [Related]
14. The protective role of FTY720 in promoting survival of allograft fat in mice.
Yi Y; Hu WJ; Zhao CR; Xiong MC; Zhang Q; Wu YP; Zeng H; Zeng N
Kaohsiung J Med Sci; 2022 Sep; 38(9):889-896. PubMed ID: 35833419
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
Chun J; Hartung HP
Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
[TBL] [Abstract][Full Text] [Related]
16. Fingolimod is a potential novel therapy for multiple sclerosis.
Aktas O; Küry P; Kieseier B; Hartung HP
Nat Rev Neurol; 2010 Jul; 6(7):373-82. PubMed ID: 20551946
[TBL] [Abstract][Full Text] [Related]
17. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
[TBL] [Abstract][Full Text] [Related]
18. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).
Chun J; Brinkmann V
Discov Med; 2011 Sep; 12(64):213-28. PubMed ID: 21955849
[TBL] [Abstract][Full Text] [Related]
19. FTY720: a most promising immunosuppressant modulating immune cell functions.
Zhang Z; Schluesener HJ
Mini Rev Med Chem; 2007 Aug; 7(8):845-50. PubMed ID: 17692046
[TBL] [Abstract][Full Text] [Related]
20. FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination.
Blanc CA; Rosen H; Lane TE
J Neuroinflammation; 2014 Aug; 11():138. PubMed ID: 25138356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
